Recent Conference Presentations

Multilevel Repeated-Measures Mixed Effects Model for Carotid Intima-Media Thickness (CIMT) Data. Statisticians in the Pharmaceutical Industry Conference, May 2006.

Repeated-Measures multi-level modelling of thickness of the carotid artery. Joint Conference of the Royal Statistical Society and Statisticians in the Pharmaceutical Industry, July 2005.

  1. Effect of Rosuvastatin on Progression of Carotid Intima Media Thickness in Low-Risk Individuals: Results of the METEOR Study. John R. Crouse III, MD; Joel S. Raichlen; Ward A. Riley; Gregory W. Evans; Mike K. Palmer; Daniel H. O'Leary; Diederick E. Grobbee; Michiel L. Bots, on behalf of the METEOR Study Group Accepted for publication JAMA 2007.
  2. Efficacy and Safety of rosuvastatin 40 mg vs atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Lawrence A Leiter, Robert S Rosenson, Evan Stein, John PD Reckless, Karl-Ludwig Schulte, Margo Schleman, Paul Miller, Michael Palmer and Froukje Sosef. Atherosclerosis (2007) article in press.
  3. Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study. Crouse JR III, Grobbee DE, O'Leary DH, Bots ML, Evans GW, Palmer MK, Riley WA, Raichlen JS; METEOR Study Group. Current Medical Research and Opinion 2007; 23: 641-648.
  4. Comparison of the Efficacy and Safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia- Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Michael B Clearfield, John Amerena, Jean-Pierre Bassand, Hugo R Hernandez-Garcia, Sam S Miller, Froukje FM Sosef, Michael K Palmer, and Brian S Bryzinski. Trials, 7: 35, 2006.
  5. Measuring Effects on Intima Media Thickness: an Evaluation of Rosuvastatin in Subclinical Atherosclerosis - The Rationale and Methodology of the METEOR study. JR Crouse, DE Grobbee, DH O’Leary, JJP Kastelein, ML Bots, GW Evans, MK Palmer, WA Riley, JS Raichlen. Cardiovascular Drugs and Therapy 18: 233-240, 2004.
  6. Rosuvastatin enhances lipid fluidity in atherogenic apoB-containing lipoproteins. R Prassl, M Caslake, C J Packard, M Palmer, J M Chapman, P N Durrington and P Laggner. Atherosclerosis Supplements, 3 (2), 187, abs 562, (2002).
  7. Goserelin versus CMF as Adjuvant Therapy in Premenopausal patient with Node-Positive Breast Cancer:  the ZEBRA Study. W Jonat, M Kaufmann, W Sauerbrei, R Blamey, J Cuzick, M Namer, I Fogelman, JC de Haes, A de Matteis, A Stewart, W Eiermann, I Szakolczai, M Palmer, M Schumacher, M Geberth, B Lisboa, on behalf of ZEBRA Trialists Group. Journal of Clinical Oncology, 2002; 20 (24): 4628-4635
  8. Clinical Determinants of survival in patient with S. Fluorouracil-based treatment for metastatic colorectal cancer: result of a multivariate analysis of 3825 patients. C-H Kohn, D Cunningham, F Di Costanzo, B Glimelius, G Blizham, A Aranda, W Scheithauer, P Rougier, M Palmer, J Wils, B Baron, F Pignatti, P Schoffski, S Micheel and H Hecker. Annals of Oncology 13 October, 308-317, 2002.

View the full list of publications...

Copyright © - Mike Palmer, 2007-2010. Privacy Policy. All Rights Reserved.
Website design and hosting by Uxello.